FGF23 Inhibition Improves Hematopoietic Stem Cell Transplantation in β-Thalassemia

Clinical evidence has established a link between anemias and skeletal abnormalities, although the underlying molecular mechanisms remain elusive. β-thalassemia (βThal) represents a valuable model for studying congenital anemia and associated bone and bone marrow (BM) microenvironment defects. Osteoporosis has a high morbidity in βThal patients, and we demonstrated that impaired hematopoietic stem cell (HSC) function is due to the prolonged persistence in an altered βThal BM niche ( Aprile et al, 2020). The correction of the genetic cause of βThal, mutations in the β-globin gene, is achieved by transplantation of HSCs from healthy donors or autologous HSCs from patients upon gene therapy. In both scenarios, a comprehensive understanding of HSCs and the BM niche is crucial to obtain successful outcomes. Our research focused on the role of fibroblast growth factor 23 (FGF23), a phosphaturic hormone at the crossroads of bone and erythropoiesis. We demonstrated that the elevated erythropoietin characteristic of the disease, leads to increased FGF23 production in both the βThal mouse model ( th3) and βThal patients, negatively affecting bone homeostasis and the interaction between HSCs and the stromal niche. Notably, in vivo FGF23 inhibition by cFGF23 peptide in th3 mice fully rescued bone defects, BM niche and HSC function ( Aprile, Raggi et al, 2023). To mimic the allogenic transplantation, we transplanted wt and th3 cells in a competitive setting into untreated th3 or th3+cFGF23 recipients. We observed partially enhanced engraftment in the cFGF23-treated mice indicating that FGF23 inhibition improves the supportive capacity of the damaged niche. We hypothesized that prolonged cFGF23 administration to recipient mice after transplantation could further restore the BM niche and boost the graft, thus achieving therapeutic outcomes. To establish the proper dose regimen with withdrawal periods for prolonged cFGF23 treatment, we analyzed bone mineral density (BMD) and HSC cell cycle at 1 and 2 weeks after discontinuing cFGF23 administration. Our results showed that rescued BMD was sustained after the discontinuation of treatment for 1 and 2 weeks ( th3 vs. th3+cFGF23 _1wk vs. th3+cFGF23_2wks: 125.9±3.8 vs. 181±19.9 vs. 142±1.6 mg/cm 3, p